Guardant Health (GH) PT Raised to $55 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Raymond James Reiterates Outperform Rating on Guardant Health (GH)
January 21, 2025 1:00 PM ESTRaymond James analyst Andrew Cooper reiterated an Outperform rating and $39.00 price target on Guardant Health (NASDAQ: GH)
The analyst comments "Net-net, this coverage news offers avenues for both volume and ASP accelerations for Reveal specifically and for the broader Guardant portfolio overall.... More
Raymond James Reiterates Outperform Rating on Guardant Health (GH)
January 21, 2025 1:00 PM ESTRaymond James analyst Andrew Cooper reiterated an Outperform rating and $39.00 price target on Guardant Health (NASDAQ: GH)
The analyst comments "Net-net, this coverage news offers avenues for both volume and ASP accelerations for Reveal specifically and for the broader Guardant portfolio overall.... More
TD Cowen Reiterates Buy Rating on Guardant Health (GH)
January 21, 2025 11:50 AM ESTTD Cowen analyst Dan Brennan reiterated a Buy rating and $42.00 price target on Guardant Health (NASDAQ: GH).
The analyst comments "This morning GH announced its MRD test, Reveal, received MolDX coverage in the recurrence CRC setting. Mgmt guided for such approval... More
